Home | About PM | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Pharmacognosy Magazine
Search Article 
  
Advanced search 
 
ORIGINAL ARTICLE
Year : 2022  |  Volume : 18  |  Issue : 78  |  Page : 304-313

Efficacy of bisacurone in bone fracture healing process: An experimental study on osteoporotic rats


1 Department of Orthopedics, The Fourth People's Hospital of Shaanxi, Xi'an, China
2 Department of Maxillofacial Oncology, The Third Affiliated Hospital of Air Force Military Medical University, Xi'an, China
3 Department of Blood Transfusion, The First Affiliated Hospital of Air Force Military Medical University, Xi'an, China

Correspondence Address:
Huixiao Li
Department of Orthopedics, The Fourth People's Hospital of Shaanxi, Xi'an - 710043
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/pm.pm_450_21

Rights and Permissions

Background: Osteoporosis (OP) is a common disorder resulting in bone fragility and fracture. Due to OP, bone mass and microarchitectural bone tissues are damaged, increasing the risk of fracture. Objectives: To determine the efficacy of bisacurone in healing fractured bones and its inflammatory response in ovariectomy (OVX)-induced OP in female rats. Materials and Methods: After inducing fracture in femur bone, bisacurone (25, 50, and 100 μg/kg) and alendronate (20 mg/kg) were orally administered to rats for 8 weeks. Subsequently, its fracture healing and anti-inflammatory potential were evaluated via assessment of various biochemical and molecular parameters. Results: Bisacurone therapy significantly (P < 0.05) increased the calcium content, serum calcium, and phosphorus in OVX-induced OP rats. It significantly (P < 0.05) reduced the serum alkaline phosphate (ALP); urine biochemical parameters such as urinary calcium, phosphorus, and creatinine; and inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor α (TNF-α). Moreover, bisacurone was found to be significantly (P < 0.05) effective in downregulating the bone turnover markers such as osteocalcin, receptor activator of nuclear factor-kappa-γ ligand (RANKL), peroxisome proliferator-activated receptor gamma (PPAR-γ), and upregulating osteoprotegerin (OPG), runt-related transcription factor 2 (Runx2), and AMP-activated protein kinase (AMPK) in OVX-induced OP rats. Conclusion: Bisacurone effectively healed the fracture and improved the bone quality in arthritic conditions by reducing inflammatory cytokines and altering the level of bone turnover markers. Therefore, bisacurone therapy should be considered for the management of fracture healing process in the arthritic conditions.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed132    
    Printed8    
    Emailed0    
    PDF Downloaded23    
    Comments [Add]    

Recommend this journal